Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 3Breast 1

Conditions

Breast Neoplasms 6Neoplasm Metastasis 2Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Advanced Breast Cancer (Parts 1 and 2) 1

Interventions

Cyclophosphamide 4Flow Cytometry 3Surveys and Questionnaires 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Methylprednisolone 2Methods 2Melphalan 2Immunologic Techniques 2Filgrastim 2Data Collection 2Blood Specimen Collection 2Azacitidine 2Alemtuzumab 2tanespimycin 1sargramostim 1ruxolitinib 1rucaparib 1ribociclib 1pembrolizumab 1motexafin gadolinium 1liposomal doxorubicin 1fludarabine phosphate 1flt3 ligand protein 1dexamethasone acetate 1dexamethasone 21-phosphate 1cc-486 1bosutinib 1aldesleukin 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × bosutinib × Breast × Clear all
NCT00777530 2008-10-23

Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 1 Completed
48 enrolled
BreastOther hematologic neoplasm

Breast Neoplasms, Leukemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡